Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report fourth-quarter fiscal 2024 results on Nov. 7, before market open.In the last reported quarter, the company’s earnings per share (EPS) of $3.50 surpassed the Zacks Consensus Estimate by 5.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and matched once, delivering an earnings surprise of 6.2%, on average.Let’s check out the factors that have shaped BDX’s performanc ...

I'm an individual investor looking to grow my wealth over the long term. I've tried many different styles of investing over the last 25 years and have found that buying dividend growth stocks and reinvesting the dividends is one of the easiest ways to grow wealth over the long term. Over the years, I've owned stocks, options, ETFs, treasury notes, and mutual funds. I operate a blog, HarvestingDividends.com, that provides information on the S&P Dividend Aristocrats and other dividend growth stocks.Analyst’s ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently launched the new BD Intraosseous (IO) Vascular Access System.The BD IO system is likely to enable access to rapid delivery of fluids or medication in critical emergency situations. The procedure involves inserting a needle into the bone marrow cavity when intravenous (IV) access is challenging or delayed.Likely Trend of BDX Stock Following the NewsFollowing the announcement, shares of the company moved nearly 1.3% south to $233.6 at yeste ...

Becton Dickinson (BDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nov ...

Core Insights - BD (Becton, Dickinson and Company) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in critical emergency situations [1][2][3] - The system allows for quick access to the circulatory system for both adult and pediatric patients, enhancing emergency care capabilities [2][3] Product Features - The BD® IO System is the only intraosseous device that can be placed after the extension set is attached and includes integrated passive needle tip safety to protect against needlestick injuries [2] - It features a rechargeable battery that extends the drill's life up to 12 times compared to non-rechargeable competitive drills, along with a multi-light battery indicator for instant battery status [2] - The device can accommodate a broad range of patients with five needle lengths and can be stabilized on various anatomical contours [2] Clinical Significance - In emergency situations, the placement of an intraosseous (IO) line is twice as likely to be successful compared to peripheral IV or central venous catheter placement, especially in patients with low or no palpable blood pressure [3] - Trained inserters achieve a 93-97 percent success rate in IO placement, indicating the reliability of the procedure [3] Availability - The BD® IO System is now commercially available to customers in the U.S. [4]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the he ...

Becton, Dickinson and Company (BDX) , popularly known as BD, announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits, BD OMICS-One XT Library Preparation Reagent Kits, yesterday. The automated solution from the BD and Hamilton collaboration will likely enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies. The solution includes the newly-released BD OMICS-One XT WTA Assay and the Hamilton M ...

Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J., Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single- ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Becton Dickinson (BDX) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat. This medical device manufacturer has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for th ...

Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J., Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its fiscal 2024 fourth quarter and full year on Thursday, Nov. 7, 2024. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news rel ...